title: Targeting ATM-deficient CLL through interference with DNA repair pathways.
abstract: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western world and accounts for approximately 30% of adult leukemias and 25% of non-Hodgkin lymphomas. The median age at diagnosis is 72 years. During recent years numerous genetic aberrations have been identified that are associated with an aggressive course of the disease and resistance against genotoxic chemotherapies. The DNA damage-responsive proapoptotic ATM-CHK2-p53 signaling pathway is frequently mutationally inactivated in CLL either through large deletions on chromosome 11q (ATM) or 17p (TP53), or through protein-damaging mutations. Here, we focus on the role of ATM signaling for the immediate DNA damage response, DNA repair and leukemogenesis. We further discuss novel therapeutic concepts for the targeted treatment of ATM-defective CLLs. We specifically highlight the potential use of PARP1 and DNA-PKcs inhibitors for the treatment of ATM-mutant CLL clones. Lastly, we briefly discuss the current state of genetically engineered mouse models of the disease and emphasize the use of these preclinical tools as a common platform for the development and validation of novel therapeutic agents.
authors.affiliation: Department of Internal Medicine, University Hospital of Cologne Cologne, Germany ; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne Cologne, Germany.
authors.forename: Gero
authors.initials: G
authors.lastname: Knittel
authors.affiliation: Department of Internal Medicine, University Hospital of Cologne Cologne, Germany ; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne Cologne, Germany.
authors.forename: Paul
authors.initials: P
authors.lastname: Liedgens
authors.affiliation: Department of Internal Medicine, University Hospital of Cologne Cologne, Germany ; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne Cologne, Germany.
authors.forename: Hans C
authors.initials: HC
authors.lastname: Reinhardt
keywords: DNA damage response; DNA-PKcs inhibitor; PARP inhibitor; chronic lymphocytic leukemia; precision medicine